WA-AMAZON-WEB-SERVICES
14.10.2021 06:03:11 CEST | Business Wire | Press release
Today, Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that NXP Semiconductors N.V. has selected AWS as its preferred cloud provider and is migrating the vast majority of its electronic design automation (EDA) workloads from NXP data centers to AWS. Running on the world’s leading cloud extends NXP’s efficiency and competitive edge in the design and verification of advanced semiconductors tailored to the requirements of automotive, industrial Internet of Things (IoT), mobile, and communications infrastructure businesses. The Netherlands-based company uses AWS’s proven global infrastructure and capabilities in high performance computing (HPC), storage, analytics, and machine learning to enhance collaboration and EDA throughput across dozens of its worldwide design centers, as well as to reduce costs with elastic scaling of compute resources and minimize scheduling risks for design projects. In addition, thanks to AWS’s virtually unlimited scale, NXP engineers gain more time to focus on innovation rather than managing compute resources.
Running on AWS, NXP aims to achieve long-term process improvements that transform how semiconductors are designed and tested. Before NXP can manufacture new chips, its designs undergo extensive testing and validation through the EDA process to ensure they are functionally safe, secure, high quality, and highly performant. NXP’s complex EDA workflows include front-end design, performance simulation, and verification, along with backend workloads that include timing and power analysis, design rule checks, and other applications to prepare a chip for production. Historically, semiconductor companies run these highly iterative workflows from on-premises data centers with fixed compute capacity. However, because of the massive compute power involved for each cycle and the increasing complexity of chip designs, producing a new device can take many months or even years unless the companies accurately forecast and install additional compute infrastructure. In contrast, by powering its EDA with AWS, NXP gains the scale and agility to advance multiple projects at the same time on demand, regardless of their complexity, and run dozens of performance simulations in parallel to accelerate time to result.
To better manage the scale and complexity of its design activities, NXP relies on AWS analytics and machine learning services to continuously refine its research and development workflows. NXP uses Amazon QuickSight (AWS’s machine learning-powered business intelligence service built for the cloud) to generate more powerful engineering and operational insights that help increase workflow efficiency. For example, by rapidly translating results from one step of testing into modifications for another, NXP can reduce the time required to iterate chip designs. NXP also uses Amazon SageMaker (AWS’s service that helps developers and data scientists build, train, and deploy machine learning models quickly in the cloud and at the edge) to optimize how it structures compute, storage, and third-party software application licenses. To support this work, NXP is building a data lake on AWS using Amazon Simple Storage Service (Amazon S3) and AWS Glue (AWS’s service for simply and cost-effectively extracting, transforming, and loading data).
In addition, NXP takes advantage of AWS’s range of specialized instances for HPC to further streamline its EDA workflows. The selection of instance types allows NXP to meet the unique requirements of each design project while also achieving a high degree of price performance. NXP uses Amazon FSx for Lustre (AWS’s service that provides cost-effective, high-performance, scalable storage for compute workloads like EDA) to store petabytes of design simulation data and make it quickly available for analysis.
“We believe cloud-based EDA is critical to accelerating semiconductor innovation and getting new designs to market faster to power an increasingly digital world where more and more devices and infrastructure are connected. AWS gives us the best scale, global presence, and selection of compute and storage options, with continuous improvements in price performance, that we need,” said Olli Hyyppa, CIO and senior vice president, NXP Semiconductors N.V. “We’re excited to expand our relationship with AWS to power the next generation of EDA workloads in the cloud. This will give precious time back to our design engineers to focus on innovation and lead the transformation of the semiconductor industry.”
“At AWS, we consider ourselves to be a community of builders, and this engagement with NXP reinforces what’s possible when you free builders to work in the best environments, with the infrastructure and capabilities they need,” said Dave Brown, vice president of Amazon Elastic Compute Cloud, Amazon Web Services, Inc. “By shifting their EDA workloads to AWS, NXP designers will have access to the best tools available for collaborating on semiconductor design and development around the world. This move will help NXP produce chips that power innovation in IoT, connected cars, and more. We’re proud to support a leading driver of innovation in the semiconductor industry, and we look forward to seeing what becomes possible when chip design moves to the cloud at such a large scale.”
About Amazon Web Services
For over 15 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud offering. AWS has been continually expanding its services to support virtually any cloud workload, and it now has more than 200 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 81 Availability Zones within 25 geographic regions, with announced plans for 24 more Availability Zones and eight more AWS Regions in Australia, India, Indonesia, Israel, New Zealand, Spain, Switzerland, and the United Arab Emirates. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com
.
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. For more information, visit amazon.com/about
and follow @AmazonNews.
About NXP Semiconductors
NXP Semiconductors N.V. (NASDAQ: NXPI) enables secure connections for a smarter world, advancing solutions that make lives easier, better, and safer. As the world leader in secure connectivity solutions for embedded applications, NXP is driving innovation in the automotive, industrial & IoT, mobile, and communication infrastructure markets. Built on more than 60 years of combined experience and expertise, the company has approximately 29,000 employees in more than 30 countries and posted revenue of $8.61 billion in 2020. Find out more at www.nxp.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013006195/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
